Aronora is a translational biotechnology company engaged in the early-stage commercial development of proprietary biologic therapeutics, including recombinant monoclonal antibodies and enzymes.
Rational design of our innovative therapeutic agents is expected to result in drug products with a superior safety profile that reduce the progression and growth of life-threatening blood clots without the detrimental bleeding side effects that characterize all currently marketed antithrombotic drugs. Our products are intended to be used in difficult-to-treat, severe, rapidly progressing, or catastrophic thrombotic blood clotting diseases and their consequences. These high mortality diseases typically represent medical emergencies that currently have no causal field treatments.
The targeted disease (indication) include suspected or verified stroke and heart attack, transient ischemic attack (TIA), pulmonary thrombo-embolism from deep vein thrombosis (DVT), major traumatic head and other crush injury-associated blood clots (thrombosis), severe progressive infections and sepsis that may be associated disseminated intravascular coagulation (DIC) and bleeding (hemorrhage) [listeria, anthrax, ebola, marburg, dengue, yersinia, etc.], and several others.
Building on the company’s ground-breaking rational approaches to superior drug safety, Aronora’s product candidates have the potential to become first-in-class medical emergency therapeutics to treat life-threatening acute thrombotic vascular diseases early, in the field, even before the patient is hospitalized and the diagnosis is verified.
In the News…
Portland, Oregon 97239
455 Mission Bay Blvd South, Suite 145
San Francisco, CA 94158